John J. Suschak

1.2k total citations · 1 hit paper
30 papers, 819 citations indexed

About

John J. Suschak is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, John J. Suschak has authored 30 papers receiving a total of 819 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 14 papers in Infectious Diseases and 7 papers in Immunology. Recurrent topics in John J. Suschak's work include Viral Infections and Outbreaks Research (9 papers), Viral Infections and Vectors (8 papers) and Liver Disease Diagnosis and Treatment (6 papers). John J. Suschak is often cited by papers focused on Viral Infections and Outbreaks Research (9 papers), Viral Infections and Vectors (8 papers) and Liver Disease Diagnosis and Treatment (6 papers). John J. Suschak collaborates with scholars based in United States, Switzerland and India. John J. Suschak's co-authors include Connie S. Schmaljohn, James A. Williams, Shan Lu, Katherine A. Fitzgerald, Shixia Wang, Charles J. Shoemaker, Collin J. Fitzpatrick, Aura R. Garrison, Joseph W. Golden and Catherine V. Badger and has published in prestigious journals such as The Lancet, Circulation and The Journal of Immunology.

In The Last Decade

John J. Suschak

29 papers receiving 791 citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study

2024 65 citations Stephen A. Harrison, Sarah Browne et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John J. Suschak United States	15	371	287	260	202	107	30	819
Vidita Choudhry United States	12	521 1.4×	178 0.6×	331 1.3×	554 2.7×	56 0.5×	15	1.1k
Jordana Grazziela Alves Coelho-dos-Reis Brazil	16	121 0.3×	281 1.0×	132 0.5×	191 0.9×	125 1.2×	58	649
Philippe Pérot France	14	272 0.7×	67 0.2×	134 0.5×	92 0.5×	37 0.3×	29	574
Puck B. van Kasteren Netherlands	15	451 1.2×	355 1.2×	300 1.2×	214 1.1×	55 0.5×	32	1.0k
Patrick Hong United States	12	171 0.5×	337 1.2×	303 1.2×	247 1.2×	33 0.3×	17	832
Jan Woraratanadharm United States	13	488 1.3×	339 1.2×	338 1.3×	258 1.3×	232 2.2×	18	1.1k
Ramona Mögling Netherlands	13	307 0.8×	369 1.3×	134 0.5×	242 1.2×	200 1.9×	22	875
J. K. Chantler Canada	19	207 0.6×	171 0.6×	191 0.7×	476 2.4×	46 0.4×	36	906
Jérôme Dellacasagrande France	12	176 0.5×	261 0.9×	129 0.5×	73 0.4×	144 1.3×	16	647
Pablo Schierloh Argentina	21	471 1.3×	642 2.2×	118 0.5×	309 1.5×	33 0.3×	33	996

Countries citing papers authored by John J. Suschak

Since Specialization

Citations

This map shows the geographic impact of John J. Suschak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John J. Suschak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John J. Suschak more than expected).

Fields of papers citing papers by John J. Suschak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John J. Suschak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John J. Suschak. The network helps show where John J. Suschak may publish in the future.

Co-authorship network of co-authors of John J. Suschak

This figure shows the co-authorship network connecting the top 25 collaborators of John J. Suschak. A scholar is included among the top collaborators of John J. Suschak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John J. Suschak. John J. Suschak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Noureddin, Mazen, Stephen A. Harrison, Rohit Loomba, et al.. (2025). Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. The Lancet. 406(10520). 2644–2655. 2 indexed citations

Browne, Sarah, John J. Suschak, Shaheen Tomah, et al.. (2025). Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Reports. 7(11). 101483–101483.

Alkhouri, Naim, Shaheen Tomah, John J. Suschak, et al.. (2024). WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial. Journal of Hepatology. 80. S515–S515. 1 indexed citations

Harrison, Stephen A., Sarah Browne, John J. Suschak, et al.. (2024). Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Journal of Hepatology. 82(1). 7–17. 65 indexed citations breakdown →

Harrison, Stephen A., Shaheen Tomah, John J. Suschak, et al.. (2023). Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial. Journal of Hepatology. 78. S54–S55. 4 indexed citations

Golden, Joseph W., Collin J. Fitzpatrick, John J. Suschak, et al.. (2023). Induced protection from a CCHFV-M DNA vaccine requires CD8+ T cells. Virus Research. 334. 199173–199173. 18 indexed citations

Hassert, Mariah, Katherine E. Schwetye, Jianfeng Zhang, et al.. (2023). The role of vaccination route with an adenovirus-vectored vaccine in protection, viral control, and transmission in the SARS-CoV-2/K18-hACE2 mouse infection model. Frontiers in Immunology. 14. 1188392–1188392. 2 indexed citations

Suschak, John J., Sandra L. Bixler, Catherine V. Badger, et al.. (2022). A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge. npj Vaccines. 7(1). 46–46. 13 indexed citations

Plutzky, Jorge, Cristina Alonso, John J. Suschak, et al.. (2022). Abstract 13440: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators. Circulation. 146(Suppl_1). 1 indexed citations

10.

Schultz, Michael D., John J. Suschak, Davide Botta, et al.. (2022). A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts. Human Vaccines & Immunotherapeutics. 18(6). 11 indexed citations

11.

Suschak, John J., Joseph W. Golden, Collin J. Fitzpatrick, et al.. (2021). A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice. npj Vaccines. 6(1). 31–31. 36 indexed citations

12.

Suschak, John J., Lesley C. Dupuy, Charles J. Shoemaker, et al.. (2020). Nanoplasmid Vectors Co-expressing Innate Immune Agonists Enhance DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus. Molecular Therapy — Methods & Clinical Development. 17. 810–821. 23 indexed citations

13.

Terry, Frances, Leonard Moise, Drew Hannaman, et al.. (2017). An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice. Human Vaccines & Immunotherapeutics. 13(12). 2824–2836. 24 indexed citations

14.

Garrison, Aura R., Charles J. Shoemaker, Joseph W. Golden, et al.. (2017). A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. PLoS neglected tropical diseases. 11(9). e0005908–e0005908. 80 indexed citations

15.

Suschak, John J. & Connie S. Schmaljohn. (2017). Future Approaches to DNA Vaccination Against Hemorrhagic Fever Viruses. Methods in molecular biology. 1604. 339–348. 2 indexed citations

16.

Suschak, John J., James A. Williams, & Connie S. Schmaljohn. (2017). Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity. Human Vaccines & Immunotherapeutics. 13(12). 2837–2848. 191 indexed citations

17.

Suschak, John J., et al.. (2010). Characterization of a SHIV162P3 variant evolved in an infected rhesus macaque with persistent plasma viremia. Virus Research. 151(2). 229–234. 5 indexed citations

18.

Polacino, Patricia, Kay Larsen, Lindsey Galmin, et al.. (2008). Differential pathogenicity of SHIV_{SF162 P4} infection in pig‐tailed and rhesus macaques. Journal of Medical Primatology. 37(s2). 13–23. 27 indexed citations

19.

Cristillo, Anthony D., Lindsey Galmin, Lauren Hudacik, et al.. (2008). HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat. Biochemical and Biophysical Research Communications. 370(1). 22–26. 8 indexed citations

20.

Cristillo, Anthony D., Julianna Lisziewicz, Leilei He, et al.. (2007). HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology. 366(1). 197–211. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact